Stevanato Group SpA
NYSE:STVN
Intrinsic Value
Stevanato Group SpA engages in the provision of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. [ Read More ]
The intrinsic value of one
STVN
stock under the Base Case scenario is
22.18
USD.
Compared to the current market price of 27.31 USD,
Stevanato Group SpA
is
Overvalued by 19%.
Stevanato Group SpA's market capitalization is 7.2B USD.
STVN stock price is 27.31 USD.
STVN stock (22.18 USD) is 19% less than its price (27.31 USD).
STVN stock price (27.31 USD) is 16% less than its Relative Value (32.55 USD). Open Relative Valuation
STVN has upside potential of 28% compared to the average analyst price target.
Open Wall St Estimates
STVN's ROIC (Return on Invested Capital) for the past 12 months is positive and is equal to 11%.
STVN's ROE (Return on Equity) for the past 12 months is positive and is equal to 14%.
STVN's Revenue has grown by 10% over the past 12 months.
STVN's ROIC (Return on Invested Capital) has decreased in the last 3 years from 14% to 11%.
STVN has positive Net Income for the last twelve months.
STVN has positive three-year average ROIC (Return on Invested Capital): 13%. The company is efficient at using invested capital to generate operating income.
STVN's Revenue is forecast to grow at a rate of 11% per year over the next 3 years.
STVN has positive Operating Income for the last twelve months.
STVN's short-term assets (862m EUR) exceed its short-term liabilties (574m EUR).
STVN has positive three-year average ROE (Return on Equity): 17%. The company is efficient at transforming stockholders' equity into net income.
STVN's Revenue has been growing by 18% per year for the last 3 years.
STVN has positive Gross Profit for the last twelve months.
STVN's ROE (Return on Equity) has significantly decreased in the last 3 years from 32% to 14%.
STVN's long-term assets (2B EUR) exceed its long-term liabilties (939m EUR).
STVN has negative Free Cash Flow for the last twelve months.
STVN has positive Net Debt. This means that the company has more debt (339m EUR) than cash and short-term investments (74m EUR).
STVN's D/E (Debt to Equity) is very low and is equal to 0.3.
STVN's Altman Z-Score is very high and is equal to 6.4.
STVN earns more than enough operating income (213m EUR) to safely cover interest payments on its debt (3m EUR).
Valuation Backtest
Stevanato Group SpA
Run backtest to discover the historical profit from buying and selling
STVN
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Stevanato Group SpA
Balance Sheet Decomposition
Stevanato Group SpA
| Current Assets | 861.9m |
| Cash & Short-Term Investments | 74m |
| Receivables | 532.6m |
| Other Current Assets | 255.3m |
| Non-Current Assets | 1.2B |
| Long-Term Investments | 5.7m |
| PP&E | 1B |
| Intangibles | 81m |
| Other Non-Current Assets | 76.3m |
| Current Liabilities | 574.4m |
| Accounts Payable | 277.8m |
| Short-Term Debt | 84m |
| Other Current Liabilities | 212.6m |
| Non-Current Liabilities | 364.7m |
| Long-Term Debt | 255.2m |
| Other Non-Current Liabilities | 109.5m |
Earnings Waterfall
Stevanato Group SpA
|
Revenue
|
1.1B
EUR
|
|
Cost of Revenue
|
-734.9m
EUR
|
|
Gross Profit
|
350.5m
EUR
|
|
Operating Expenses
|
-137.5m
EUR
|
|
Operating Income
|
213m
EUR
|
|
Other Expenses
|
-67.4m
EUR
|
|
Net Income
|
145.6m
EUR
|
Free Cash Flow Analysis
Stevanato Group SpA
STVN Profitability Score
Profitability Due Diligence
Stevanato Group SpA's profitability score is 52/100. The higher the profitability score, the more profitable the company is.
Score
Stevanato Group SpA's profitability score is 52/100. The higher the profitability score, the more profitable the company is.
STVN Solvency Score
Solvency Due Diligence
Stevanato Group SpA's solvency score is 76/100. The higher the solvency score, the more solvent the company is.
Score
Stevanato Group SpA's solvency score is 76/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
STVN Price Targets Summary
Stevanato Group SpA
According to Wall Street analysts, the average 1-year price target for
STVN
is 35.07 USD
with a low forecast of 30.3 USD and a high forecast of 39.9 USD.
Shareholder Return
STVN Price
Stevanato Group SpA
| Average Annual Return | -4.55% |
| Standard Deviation of Annual Returns | 19.35% |
| Max Drawdown | -51% |
| Market Capitalization | 7.2B USD |
| Shares Outstanding | 265 500 000 |
| Percentage of Shares Shorted | 4.92% |
Company Profile
Stevanato Group SpA
Country
Industry
Market Cap
Dividend Yield
Description
Stevanato Group SpA engages in the provision of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. The company is headquartered in Piombino Dese, Padova and currently employs 4,652 full-time employees. The company went IPO on 2021-07-16. The firm delivers products, processes, and services across all stages of drug developments, including pre-clinical, clinical, and commercialization. Its Engineering segment includes the equipment and technologies developed and provided to support the end-to-end pharmaceutical, biotechnology, and diagnostic manufacturing processes. The firm operates locally, in Europe, and globally, including Brazil, China, Mexico, and the United States.
Contact
IPO
Employees
Officers
The intrinsic value of one
STVN
stock under the Base Case scenario is
22.18
USD.
Compared to the current market price of 27.31 USD,
Stevanato Group SpA
is
Overvalued by 19%.
You don't have any saved screeners yet
